
Opinion|Videos|March 11, 2025
Quality of Life and Patient Outcomes in mCRC Treatment
Experts discuss practical strategies used by their institutions to manage treatment-related toxicities with third-line therapies for metastatic colorectal cancer (mCRC) and share their experiences on how third-line therapy options have impacted patients’ quality of life.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What practical strategies does your institution use to manage treatment-related toxicities with third-line therapies for mCRC?
- In your experience, how have the third-line therapy options impacted your patients’ quality of life?
Advertisement
Related to this article

A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.

The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.

Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.

Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.

TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.

Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.

Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
NEI Director Highlights Pediatric Advances, AI’s Promise in Eye Care
3
GLP-1s Have Protective Benefit Against DME, Glaucoma Surgery
4
Keynote Address Tackles AI’s Role in Health Care, Eye Care
5

